RARE in the 13F filings
Ultragenyx Pharmaceutical In · CUSIP 90400D108
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 24 May 2024
- latest of these filings; the earliest 14 May 2024
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 8 listed it in both
- Shares listed
- 10,990,603
- combined, among listed positions
- Reported value
- $513m
- combined, at the quarter end
Among the 93 comparable managers: 7 buyers (opened or added shares) and 3 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing RARE in Q1 2024
12 of 12 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 3,568,873 shares now+120,175
- Farallon Capital Management LLCnew position · 99,000 shares now+99,000
- Schonfeld Strategic Advisors LLCexisting position · 440,798 shares now+97,986
- Winton Group Ltdnew position · 8,755 shares now+8,755
- PDT Partners LLCexisting position · 52,474 shares now+4,973
Reductions
- Marshall Wace LLPexisting position · 968,990 shares now-520,496
- Wellington Management Group LLPexisting position · 4,097,975 shares now-317,054
- Hudson Bay Capital Management LPexisting position · 305,100 shares now-184,900
New positions and exits
New (2)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2014 | 2 | $108m | n.a. | n.a. |
| Q2 2014 | 2 | $103m | n.a. | n.a. |
| Q3 2014 | 2 | $237m | n.a. | n.a. |
| Q4 2014 | 2 | $187m | n.a. | n.a. |
| Q1 2015 | 6 | $676m | n.a. | n.a. |
| Q2 2015 | 7 | $1.2bn | n.a. | n.a. |
| Q3 2015 | 9 | $1.3bn | n.a. | n.a. |
| Q4 2015 | 9 | $1.7bn | n.a. | n.a. |
| Q1 2016 | 3 | $933m | n.a. | n.a. |
| Q2 2016 | 4 | $461m | n.a. | n.a. |
| Q3 2016 | 6 | $1.1bn | n.a. | n.a. |
| Q4 2016 | 5 | $1.2bn | n.a. | n.a. |
| Q1 2017 | 5 | $1.1bn | n.a. | n.a. |
| Q2 2017 | 3 | $661m | n.a. | n.a. |
| Q3 2017 | 3 | $505m | n.a. | n.a. |
| Q4 2017 | 5 | $532m | n.a. | n.a. |
| Q1 2018 | 6 | $655m | n.a. | n.a. |
| Q2 2018 | 6 | $1.3bn | n.a. | n.a. |
| Q3 2018 | 6 | $1.3bn | n.a. | n.a. |
| Q4 2018 | 6 | $598m | n.a. | n.a. |
| Q1 2019 | 7 | $1.3bn | n.a. | n.a. |
| Q2 2019 | 7 | $1.3bn | n.a. | n.a. |
| Q3 2019 | 6 | $767m | n.a. | n.a. |
| Q4 2019 | 6 | $685m | n.a. | n.a. |
| Q1 2020 | 6 | $791m | n.a. | n.a. |
| Q2 2020 | 5 | $1.5bn | n.a. | n.a. |
| Q3 2020 | 6 | $1.6bn | n.a. | n.a. |
| Q4 2020 | 8 | $3.0bn | n.a. | n.a. |
| Q1 2021 | 10 | $2.6bn | n.a. | n.a. |
| Q2 2021 | 14 | $2.3bn | n.a. | n.a. |
| Q3 2021 | 9 | $2.0bn | n.a. | n.a. |
| Q4 2021 | 8 | $1.6bn | n.a. | n.a. |
| Q1 2022 | 8 | $1.5bn | n.a. | n.a. |
| Q2 2022 | 8 | $1.1bn | n.a. | n.a. |
| Q3 2022 | 6 | $487m | n.a. | n.a. |
| Q4 2022 | 8 | $604m | n.a. | n.a. |
| Q1 2023 | 9 | $502m | n.a. | n.a. |
| Q2 2023 | 11 | $619m | n.a. | n.a. |
| Q3 2023 | 8 | $397m | n.a. | n.a. |
| Q4 2023 | 9 | $593m | 7 | 2 |
| Q1 2024 | 12 | $513m | 7 | 3 |
| Q2 2024 | 13 | $413m | 10 | 2 |
| Q3 2024 | 16 | $809m | 9 | 6 |
| Q4 2024 | 11 | $243m | 7 | 4 |
| Q1 2025 | 8 | $158m | 5 | 3 |
| Q2 2025 | 7 | $120m | 4 | 3 |
| Q3 2025 | 8 | $94m | 3 | 3 |
| Q4 2025 | 5 | $43m | 17 | 17 |
| Q1 2026 | 5 | $48m | 18 | 11 |
| Q2 2026 | 7 | $396m | 11 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RARE and LLY →RARE and JNJ →RARE and VRTX →Choose a stock to compare with RARE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RARE, latest filings →Back to the 13F Explorer →